Product
LASN01
Aliases
High-dose LASN01
2 clinical trials
7 indications
Indication
Pulmonary FibrosisIndication
Graves' DiseaseIndication
Eye DisordersIndication
Graves OphthalmopathyIndication
Endocrine System DiseasesIndication
Orbital DiseasesIndication
ProptosisClinical trial
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye DiseaseStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye DiseaseStatus: Recruiting, Estimated PCD: 2025-03-01